JNK-IN-7: Selective JNK Inhibitor for Advanced MAPK Signaling Research

Executive Summary: JNK-IN-7 is a potent, covalent inhibitor of c-Jun N-terminal kinases (JNK1, JNK2, JNK3), with IC₅₀ values of 1.54 nM, 1.99 nM, and 0.75 nM, respectively, under biochemical assay conditions (DMSO, pH 7.5, 25°C) (APExBIO). It binds irreversibly to Cys116 on JNK2, blocking ATP binding and downstream c-Jun phosphorylation. JNK-IN-7 demonstrates selective inhibition of IRAK-1-dependent Pellino 1 E3 ligase activity at higher concentrations (1–10 μM), affecting Toll receptor signaling in human IL-1R cells and RAW264.7 macrophages. JNK/ERK signaling is central to apoptosis in mammalian cells, including models of Candida krusei-induced bovine mastitis (Miao et al. 2023). The compound is insoluble in water/ethanol but dissolves ≥24.7 mg/mL in DMSO and must be stored at −20°C for stability (APExBIO).

Biological Rationale

The c-Jun N-terminal kinase (JNK) pathway orchestrates cellular responses to stress, inflammation, and apoptosis. JNKs phosphorylate c-Jun, which regulates transcription of genes involved in cell survival and immune modulation. Deregulation of JNK/ERK signaling is linked to inflammatory diseases, cancer, and pathogen-induced apoptosis (Miao et al. 2023). In mammalian epithelial cells, JNK activity mediates responses to infection and cytokine stimulation, with Toll-like receptor signaling as a principal upstream activator. Selective chemical inhibitors of JNK, such as JNK-IN-7 (SKU A3519, APExBIO), are critical for dissecting these pathways. The ability to modulate c-Jun phosphorylation without off-target effects on related kinases enables high-resolution studies of MAPK signaling specificity.

Mechanism of Action of JNK-IN-7

JNK-IN-7 is a covalent, irreversible inhibitor targeting the ATP-binding pocket of JNK isoforms. It forms a covalent bond with the cysteine residue Cys116 in JNK2, locking the kinase in an inactive conformation (APExBIO). This covalent interaction prevents ATP binding and substrate phosphorylation, specifically blocking c-Jun activation. In vitro assays demonstrate sub-nanomolar IC₅₀ values for JNK1 (1.54 nM), JNK2 (1.99 nM), and JNK3 (0.75 nM) at 25°C in kinase buffer with substrate peptide. JNK-IN-7 also inhibits IRAK-1-dependent E3 ligase activity of Pellino 1, a signaling protein in the Toll receptor pathway, but only at micromolar concentrations (1–10 μM). This dual activity allows for selective modulation of both kinase-dependent and innate immune pathways in cell-based models.

Evidence & Benchmarks

• JNK-IN-7 inhibits JNK1/2/3 kinase activity with IC₅₀ values of 1.54, 1.99, and 0.75 nM, respectively (APExBIO, product page).
• It covalently modifies Cys116 in JNK2, resulting in irreversible kinase inactivation (APExBIO, product page).
• At concentrations of 1–10 μM, JNK-IN-7 inhibits IRAK-1-dependent Pellino 1 E3 ligase activity, impacting Toll receptor signaling (APExBIO, product page).
• JNK/ERK signaling is required for apoptosis in bovine mammary epithelial cells after Candida krusei infection (Miao et al. 2023, DOI).
• JNK-IN-7 enables precise c-Jun phosphorylation inhibition in cell-based MAPK pathway assays (internal review).

This article extends the analysis in JNK-IN-7: Precision Tool for Dissecting JNK Signaling by providing updated quantitative data and clarifying specific use cases for inflammation research. In comparison to Translational Horizons in JNK Pathway Modulation, this work details practical workflow and compound handling for experimental reproducibility.

Applications, Limits & Misconceptions

JNK-IN-7 is widely used in research applications requiring selective JNK pathway inhibition. These include:

• Dissecting MAPK signaling in stress, apoptosis, and inflammation models.
• Inhibiting c-Jun phosphorylation in cell-based assays to quantify JNK-specific responses.
• Modulating innate immune signaling, especially in Toll receptor and IRAK-1/Pellino 1 studies.
• Validating the role of JNK in pathogen-induced apoptosis, as in C. krusei-infected bovine epithelial cells (Miao et al. 2023).

For a comprehensive systems-biology perspective, see JNK-IN-7: Selective JNK Inhibitor Empowering MAPK Pathway Research, which this article updates with new solubility and handling data.

Common Pitfalls or Misconceptions

• JNK-IN-7 is not effective in water or ethanol due to poor solubility; use only freshly prepared DMSO solutions (≥24.7 mg/mL).
• It does not inhibit kinases outside the JNK family at recommended concentrations; off-target effects are minimal in standard conditions.
• Long-term storage of solutions at room temperature or above −20°C leads to compound degradation and loss of activity.
• Inhibition of IRAK-1-dependent Pellino 1 is only observed at higher (μM) concentrations, not in typical nM-range kinase assays.
• It should not be used in clinical or veterinary diagnostics; for research use only (RUO).

Workflow Integration & Parameters

For optimal results, JNK-IN-7 should be handled as follows:

• Resuspend the solid compound in anhydrous DMSO to ≥24.7 mg/mL for stock solutions.
• Aliquot and store at −20°C; avoid repeated freeze-thaw cycles.
• Prepare working solutions fresh before each experiment; do not store diluted stocks.
• Recommended concentrations: 0.5–100 nM for kinase inhibition; 1–10 μM for IRAK-1/Pellino 1 modulation.
• In MAPK pathway and apoptosis assays, use standard controls (vehicle, positive/negative) for signal specificity.

For detailed troubleshooting and experimental design, see JNK-IN-7 (SKU A3519): Data-Driven Solutions in MAPK and Apoptosis Research, which this article complements by focusing on compound mechanism and benchmark data.

Conclusion & Outlook

JNK-IN-7 from APExBIO is a benchmark tool for selective inhibition of JNK kinases, enabling high-precision research in MAPK signaling, apoptosis, and inflammation. Its covalent mechanism ensures potency and selectivity, with well-characterized solubility and handling parameters. Integration in workflows studying pathogen-host signaling and immune response regulation is straightforward, provided proper compound management. As research advances in MAPK pathway modulation and immune signaling, JNK-IN-7 remains a critical resource for dissecting JNK-specific mechanisms in both basic and translational contexts (Miao et al. 2023).